SillaJen Presents 'BAL0891' Clinical Overview Poster at U.S. International Conference

Shinilgen announced on the 16th that the clinical research overview of the anticancer drug 'BAL0891,' currently undergoing Phase 1 clinical trials in Korea and the United States, was presented as a poster at the '2023 EORTC-NCI-AACR' symposium held in Boston, Massachusetts, USA.

SillaJen announced that it presented a poster on 'BAL0891' at the '2023 EORTC-NCI-AACR' symposium.
[Photo by SillaJen]

The EORTC-NCI-AACR symposium is an international conference jointly organized by the European Organisation for Research and Treatment of Cancer (EORTC), the U.S. National Cancer Institute (NCI), and the American Association for Cancer Research (AACR), held annually on a rotating basis between Europe and the United States. This year's symposium took place from the 11th to the 15th (local time), with the clinical research overview of BAL0891 revealed on the 14th.

BAL0891 is a mitotic checkpoint inhibitor class anticancer drug that Shinilgen licensed from the Swiss company Basilea in September last year. It is a dual-phosphorylation enzyme inhibitor that inhibits two phosphorylation enzymes: threonine tyrosine kinase (TTK) and polo-like kinase (PLK) 1.

The presented poster introduced the drug mechanism of BAL0891, preclinical results, and a comprehensive overview of the ongoing clinical trials in the United States and Korea. BAL0891 began patient enrollment targeting metastatic solid tumor patients in the United States in February and started enrollment domestically in July.

A Shinilgen representative explained the significance, stating, “The acceptance and presentation of a research overview on a drug that has just begun clinical trials at a world-renowned conference indicates the high value of the drug and great expectations for the research.”

This content was produced with the assistance of AI translation services.